Platelet Enzymatically Oxidized Phospholipids (eoxPL) Characterisation in a Healthy Cohort on and Off Aspirin

Platelet Dysfunction Due to Aspirin Clinical Trial

Official title: Platelet Enzymatically Oxidized Phospholipids (eoxPL) Characterisation in a Healthy Cohort on and Off Aspirin

Status Completed

Clinical Trial Summary

Healthy volunteers (n = 28) were recruited from the workplace (14 male, 14 female; age range 20-50 years). Ethical approval, which included informed consent, was from Cardiff University, Schools of Medicine and Dentistry Research Ethics Committee (SMREC16/02). Following a 2-week period free from non-steroidal anti-inflammatory drugs (NSAIDs), peripheral blood was obtained and platelets isolated. Participants were commenced on aspirin 75 mg once daily for seven days and then provided a repeat blood sample. Following a 2-month period, participants were invited to repeat samples pre- and post-aspirin, and again a third time 2 months later.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Platelet Dysfunction Due to Aspirin

• NCT number: NCT05604118
• Study type: Interventional
• Source: Cardiff University
• Status: Completed
• Phase: N/A
• Start date: August 1, 2016
• Completion date: June 1, 2022